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Abstract
With the aim of finding a correlation between the crystallization kinetics and the
molecular dynamics of a substance that would allow to predict its crystallization time
as a function of temperature for a given α relaxation time, we have studied Stiripentol,
an anticonvulsant drug. Stiripentol has been characterized in its supercooled liquid,
amorphous (glass) and crystalline states by the concurrent use of Broadband Dielec-
tric Spectroscopy (BDS), differential scanning calorimetry, x-ray diffraction and optical
microscopy. BDS was employed to study both the dipolar molecular dynamics and
the kinetics of crystallization from the melt. Three different molecular relaxation dy-
namics were identified: an α relaxation corresponding to the collective reorientation of
the molecules and associated with the glass transition (Tg = 246.2 ± 0.5 K), a Johari
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Goldstein β relaxation that can be associated with the single-molecule precursor of the
α process, and a γ relaxation arising from intramolecular motions. Isothermal crys-
tallization of Stiripentol was studied by means of BDS well above the glass transition
(between 273 K and 293 K) and it was observed under optical microscope at ambient
conditions. Stiripentol did not exhibit any sign of polymorphism at ambient pressure,
and it recrystallized from the melt into its stable crystalline form. The crystallization
kinetics did not obey the Avrami law. Stiripentol displayed a very low nucleation rate,
and drops of liquid Stiripentol were observed to crystallize completely from a single
nucleus before the appearance of new nuclei, so that the crystallite grew according to
the morphology of the liquid domains, a fact that might explain the lack of validity
of the Avrami law. Possible correlations between the crystallization kinetics and the
molecular dynamics have been analyzed, finding that the crystallization time has a sub-
linear dependence on the cooperative relaxation time, as is the case in other substances
reported in the scientific literature. This could suggest a general correlation of these
parameters, at least at temperatures above Tg. The low nucleation rate is an interesting
feature in the quest of possible mechanisms that allow enhancing the physical stability
of amorphous drugs.
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Introduction
Active pharmaceutical ingredients (API’s) are generally stored in solid form, either as crys-
talline or amorphous (glassy) powders.1–3 The amorphous form of API’s, though being ther-
modynamically unstable,4,5 offers some advantages: amorphous phases show more solubility
and better dissolution profiles and hence better bioavailability than crystal phases, by virtue
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of their higher free energy.6–9 It has also been reported that in some cases amorphous drugs
can be compacted into tablets more effectively than polycrystalline powders, even omitting
the addition of excipients.10 By means of formulation in amorphous phase, many drugs with
originally poor aqueous solubility have reached the drug development stage during the last
decade.11–13 Although the detailed microscopic mechanisms governing the kinetic stability of
amorphous API’s remain unknown, the crystallization kinetics appears to be determined by
a large number of factors such as preparation method, thermal and mechanical treatments
employed during formulation, storage temperature, application of pressure, or exposure to
humidity.14,15 It is then of utter importance to find out which are the mechanisms taking
place in the amorphous to crystalline transformation, so as to be able to find optimum pro-
duction and storage conditions of the formulated drug.16–22
Many factors are involved in the stability of a substance. Thermodynamic quantities such as
differences in free energy between the phases involved and interfacial energies, play a role as
they determine the stable phase of the system and the energetic cost of having a mixed-phase
sample. However, thermodynamic quantities mostly reflect equilibrium behavior, and only
to a smaller extent the kinetics to reach the equilibrium state. It is well-known that there are
two main relevant factors for the recrystallization process, thermodynamics and kinetics.23 In
this respect, it is interesting to note that a recent review indeed suggested that the molecular
mobility (rather than thermodynamic quantities) appears to be the most important factor
governing the crystallization rate.24 It is also recognized that the complexity of the problem
makes difficult, at present, the establishment of clear correlations between molecular mobility
and physical stability, mainly due to the complexity of the involved molecular entities and
their inter- and intramolecular interactions as well as due to the different time scales involved
in amorphous materials, not only the so-called ’global mobility’ which refers to the structural
relaxation (α-relaxation). As for the thermodinamical aspect of recrystallization, lowering
the temperature of the supercooled liquid decreases the steady state nucleation and growth
rates, but, according to the kinetics, it increases the liquid’s viscosity which is responsible for
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delaying the recrystallization.24 The problem is even more difficult because nucleation and
growth are commonly simultaneous effects that cannot be set apart. The case of Stiripentol
is an unusual and outstanding case because nucleation is unlikely and only growth plays a
role within the recrystallization process.
Stiripentol (STP; 1-(1,3-benzodioxol-5-yl)-4,4-dimethyl-1-penten-3-ol, C14H18O3) is an anti-
convulsant drug, structurally unrelated to the currently available antiepileptics.25 It is used
for the treatment of Dravet syndrome or severe myoclonic epilepsy in infancy (SMEI) in con-
junction with sodium valporate and clobazam when seizures are not adequately controlled
with the association of these two medications.26,27 STP is practically insoluble in water and
aqueous fluids,28,29 and hence it is commercialized in the form of gelatin capsules or in the
form of granules for a drinkable suspension (Diacomit R©). The state of the art in STP re-
search is of great impact and relevance. Around 1% of the world’s population suffer from
epilepsy of different types, among which one third still don’t have effective anti-epileptic
drugs clinically available. It has been recently reported that STP is an LDH inhibitor that
suppresses neural activity and seizures, and is in fact the first antiepileptic drug that acts on
metabolic pathways, mimicking the effect of ketogenic diets used in drug-resistant epilepsy.30
Given the low solubility of STP in water, it might be interesting if its amorphous phase could
be stabilized to improve its dissolution rate in the body and hence its bioavailability, while
avoiding crystallization. In this contribution, we study the molecular dynamics and isother-
mal crystallization of STP, and analyze the possible correlation between the crystallization
time and the characteristic time of molecular relaxations. Despite the fact that the crys-
tallization kinetics does not follow the Avrami law, we find the same sublinear correlations
between the cooperative relaxation time and the crystallization time observed in other amor-
phous drugs.31–34 Finding a correlation model between these magnitudes would be of great
interest since it would help predicting the crystallization kinetics of a substance at different
temperatures, enabling the development of stabilization protocol approaches.
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Experimental section
STP was acquired from Biocodex Laboratoire with purity higher than 99%. Differential
scanning calorimetry experiments by means of a Q100 from TA Instruments were done by
melting, cooling and reheating STP samples inside an aluminum capsule. Measurements
were performed in the temperature range from 203 K to 393 K, with a heating/cooling rate
of 2 K/min with masses arounf 10 mg and under nitrogen atmosphere.
A Novocontrol Alpha analyzer was used for Broadband Dielectric Spectroscopy (BDS) mea-
surements. The sample was placed in a stainless steel parallel-plate capacitor specially
designed for the analysis of liquids, with the two electrodes kept at fixed distance by means
of silica spacers of 50 µm diameter. Temperature control of the capacitor and thus of the
sample was achieved with a nitrogen-gas flow cryostat with an error not higher than 0.3
K. Two different BDS experiments were carried out, in order to study the relaxation dy-
namics and the crystallization kinetics of the material. In the former case, the sample in
crystalline state was placed in the capacitor, melted at 373.2 K, and quenched to 120 K
inside cryostat. Successive isothermal measurements were done every 2 K, from 180 K to
296 K in the frequency (f) range between 10−2 Hz to 106 Hz. STP exhibited three dynamic
processes, namely a collective primary relaxation at lower frequency (α process),a secondary
dynamics at higher frequency (β process) and a γ relaxation arising from intramolecular
motions. The acquired dielectric loss spectra were analyzed by fitting the loss features with
Havrilak-Negami (HN) functions. A background proportional to reciprocal frequency was
added to model the conductivity contribution to the loss spectra. The analytic expression
of the HN function without the conductivity contribution is:35,36




where ∆ = s − ∞ is the dielectric strength (equal to the step variation of ′, and
proportional to the density of the molecules taking part in the relaxation process), and
5
∞ and s are the high-frequency and static low-frequency limits of the real permittivity.
The HN exponents, a and b are related to the shape and symmetry of the relaxation time
distribution, and lie within 0 and 1. The characteristic time τ at which the dielectric loss















A special case of the HN function (Eq. (1)) is the Cole-Cole function, which corresponds
to the case that the symmetry parameter b is equal to 1, leading to symmetric relaxation
peaks.
The second BDS experiment, designed to study the isothermal crystallization kinetics of
STP, consisted in measuring the decrease of strength of the dielectric loss as a function of
time during the crystallization of the supercooled material at different fixed temperatures.
To this end, the molten sample was placed inside a precooled cryostat at 233 K (about
13 K below Tg) and then the temperature was raised at a rate of 10 K/min until reaching
the desired temperature of the experiment, (Te). We measured the recrystallization at five
different Te temperatures between 273 and 293 K in the frequency range from 102 to 106Hz.
These dielectric measurements were carried out on the same sample, which was re-melted
and re-vitrified prior to each experimental run.
In order to discard the existence of a possible polymorphism of STP at ambient pressure,
high-resolution X-ray powder diffraction data were recorded. A horizontally mounted INEL
cylindrical position-sensitive detector (CPS-120) with a Debye-Scherrer geometry was used,
with angular step of ca. 0.029◦ − 2θ over a 2θ-range from 2 to 60◦. The system works with
monochromatic CuKα1 radiation ( λ = 1.5406, 40 kV and 25 mA) and is equipped with a
liquid nitrogen 700 series Cryostream Cooler from Oxford Cryosystems (accuracy of 0.1 K).
STP samples were loaded at ambient conditions into a 0.5-mm-diameter Lindemann capillar,
which could rotate around its axis during data collection in order to minimize the effect of
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preferential orientation. Three samples were measured: the as-provided crystalline powder
(as received from the manufacturer), the supercooled liquid during the crystallization process,
and a fully recrystallized sample. The first and last were measured at ambient temperature
(300 K), while the second was studied at 273 K.
Results and discussion
Relaxation Dynamics
Fig. 1 shows the loss spectra, i.e imaginary part of the complex relative dielectric permit-
tivity, of STP in its supercooled liquid state and glass state, as measured upon heating from
low temperature (only some measurements from 140 K to 282 K are shown, for clarity).
The molecular structure of STP is shown in the inset of panel (b). A primary relaxation is
observed, visible as an asymmetric peak in the loss spectra of Fig. 1(a). This relaxation
corresponds to the collective reorientation of the STP molecules, as will be shown later.
Upon decreasing the temperature, this feature shifts to lower frequency. At low-temperature
a second relaxation (β process) is observed, indicated by the arrow at the bottom of panel a
and in the middle of panel b. Finally, for temperatures lower than 240 K, another relaxation
(γ) can be observed, as marked in panel (b). The two latter relaxations were fitted with
Cole-Cole functions.
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Figure 1: (a): Loss spectra of STP measured between 246 and 282 K. Fits of α and β
relaxations are displayed for the spectrum at 252 K. (b): Loss spectra of STP measured
between 140 and 240 K. Fits of β and γ relaxations can be seen in the measurements at 220
and 140 K, respectively. Inset: Molecular structure of STP.
The Arrhenius plot of the characteristic times (τ) corresponding to α, β and γ relaxations,
as obtained from the fitting procedure, is shown in Fig. 2. The γ relaxation follows Arrhenius
behavior with an activation energy Ea = 23.5± 0.1 J/mol K. The β relaxation displays two
different Arrhenius regimes with Ea = 98.2 ± 0.2 J/mol K below Tg, and Ea = 249 ± 5




D · TV F
T − TV F
)
(3)
were the prefactor τ0, the strength parameter D, and the Vogel - Fulcher tempera-
ture TV F are phenomenological parameters with the following values obtained from the fit:
Log(τ0/(s)) = −16.2 ± 0.3 , D = 10.3 ± 0.5 and TV F = 198 ± 1 K. The horizontal dashed
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line indicates the value of τα which is conventionally taken to mark the glass transition tem-
perature (Log(τα) = 2, i.e τα = 100 s). The intersection of the VFT fit and this dashed
line gives a glass transition temperature of Tg = 246.2 ± 0.5 K. The inset of Fig. 2 (a)
shows the calorimetry thermogram of STP, which was acquired upon heating from below Tg,
after previously cooling the sample from the molten state at a rate of 2K/min. The arrow
indicates the onset Tg value obtained from the two tangents (dashed lines), which is 248± 1
K, in agreement with the data obtained from the BDS data and with the previously reported
Tg value.38
Figure 2: Arrhenius plot of the primary (α, filled green circles) and secondary (β, purple
triangles and γ, blue empty circles) relaxation times, as extracted from the loss spectra dis-
played in Fig.1. The continuous green line is the fit of τα using the Vogel-Fulcher-Tammann
equation (Eq. 3 ). The horizontal dashed line indicates the glass transition temperature.
Pink asterisks portray the values obtained for τβ using the Coupling model (see text).39,40
Inset: Differential scanning calorimetry thermogram acquired upon heating from the glass.
The arrow indicates the onset Tg value obtained from the two tangents shown with dashed
lines.
In agreement with the VFT model, TV F is lower than Tg. The VFT temperature depen-
dence confirms that the slower (α) relaxation has a cooperative nature, which becomes more
pronounced when approaching the glass transition, which is a typical feature of correlated
glass forming systems.
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The experimental value obtained for STP is m = 93±7, which indicates this drug is a fragile
glass former.
The interpretation of secondary relaxations is not as straightforward as for the primary one; a
secondary relaxation may relate either to intramolecular motions involving the displacement
of polar side-groups, or else it may be a Johari-Goldstein relaxation. The latter type of
process involves the whole molecule and can be interpreted as the single-molecule relaxation,
precursor of the cooperative α-relaxation according to the Coupling model.39,42–45 The change
in Arrhenius temperature dependence of τβ at Tg is a characteristic feature that indicates
the β relaxation is a Johari-Goldstein process.40 This is also confirmed by the validity of
the Coupling Model according to which, the relaxation time τCM of the Johari-Goldstein






Here tc’s typical value is 2 · 10−12 s and represents a cross-over time determined by the
intermolecular interaction and independent of temperature.40,46 The parameter p is equal to
1−βKWW , where βKWW is the stretched exponent that describes the shape of the α-relaxation
process in the time domain.47 For the obtained shape parameters (a, b) of the HN function
employed to fit the primary relaxation, the following relation holds:48,49 p ∼= 1− (a · b)1/1.23.
We have calculated the corresponding time τCM with Eq. 5 and plotted the results in the
Arrhenius plot shown in Fig. 2 (pink asterisks). The calculated Coupling Model values are
virtually identical to the experimental ones. Hence, the β relaxation can be considered the
precursor of the α process and it is a whole-molecule process. Consequently, the observed γ
process must be an intramolecular process, linked to the dynamics of a subpart or side-group
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of the non-rigid STP molecule.
Crystallization kinetics
In order to characterize the crystallization process from the supercooled liquid state into the
stable crystalline state, we performed experiments at five fixed temperatures (Te) above Tg,
namely: 273.0, 275.5, 278.0, 283.0 and 293.0 K (± 0.1) K. The decrease of ∆ over time
(at a fixed temperature) is a quantitative measure of the amorphous fraction of the sam-
ple and thus of the kinetics of the (isothermal) recrystallization process, since the number
of molecules participating in the cooperative α relaxation is proportional to the dielectric
strength ∆.50 During crystal growth, in fact, some molecules are removed from the super-
cooled liquid phase (where they are mobile), and form crystallites (where all motion stops).
As an example, Fig. 3 shows the real (a) and imaginary (b) part of complex dielectric per-
mittivity, ′ and ′′ respectively, recorded at Te=278.0 K in consecutive spectra (one every
190 seconds, approximately) during crystallization. The arrows indicate the spectral changes
as crystallization progresses.
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Figure 3: Spectra of the real (a) and imaginary (b) part of complex dielectric permittivity,
′ and ′′ respectively, recorded at Te=278.0 K every 190 seconds during crystallization. The
arrows indicate the evolution in time as crystallization progresses.
It can be observed that the recrystallization process produces a decrease in the intensity
of the α relaxation peak, in the imaginary part of the dielectric permittivity, and correspond-
ingly a decrease of static permittivity s, and thus of the dielectric strength in the real part.
Fig. 4 shows the values of s at 100 Hz, during isothermal crystallization at Te = 278.0 K.
The plateau at long times indicates full crystallization of the sample. The inset to Fig. 4
shows a zoom-in at short times, where the intersection of two tangents marks the crystal-
lization onset at time to. In each series of isothermal spectra, the static permittivity was
taken to be the value of the real permittivity at a fixed frequency varying between 102 and
104 Hz depending on the measuring temperature, but always representing the low-frequency
plateau value of the real permittivity.
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Figure 4: Evolution of the real static permittivity, s, at 100 Hz as a function of time, for
the data of Fig. 3 at Te = 278.0K. The inset shows a zoom-in at short experiment times,
where the intersection of the two gray lines marks the crystallization onset.
To analyze the crystallization kinetics of STP, we have studied the time evolution of the
normalized static-permittivity difference, as defined by D’Amore et al.:51
ˆ =
s(SL)− s(t)
s(SL)− s(C) . (6)
Here, s(SL) and s(C) are the static permittivity of the supercooled liquid and the
crystalline phase, respectively. The first value can be obtained by extracting s at time
zero (right after supercooling), and the second by doing the same thing at the end of the
crystallization process, where the sample is completely crystalline and no further change is
observed in s (See Fig.4 ). s(t) is the static permittivity of the mixed-phase sample as a
function of the time elapsed from the start of the isothermal measurements. Fig. 5 shows the
ˆ values obtained for all five experiments as a function of time. At short times ˆ = 0, since
the sample is mainly in the supercooled state and the numerator vanishes. As the sample
crystallizes, the value of s(t) decreases approaching s(C), until complete crystallization
when ˆ becomes unity.
In order to find a possible correlation between the relaxation time of the α relaxation
and the characteristic crystal growth time of STP we have determined a characteristic crys-
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Figure 5: Time evolution of the normalized static-permittivity difference ˆ during crystal-
lization, as a function of the time elapsed since crystallization onset of each isothermal
measurement (logarithmic scale) Stars, diamonds, inverted triangles, squares and triangles
represent temperatures 293.0, 283.0, 278.0, 275.5 and 273.0 K respectively.
tallization time (tc), as the time interval between the crystallization onset (to) and the time
at which ˆ becomes 0.25. In Fig. 6 we plot the obtained tc values as a function of the
relaxation time of the cooperative dynamics, in logarithmic scale. For comparison, we also
display similar data obtained from the literature31 for the drugs celecoxib and indomethacin.
There is a clear correlation between the two times in all cases. A linear regression gives for
STP a slope value of (0.86± 0.07), whereas that reported for indomethacin and celecoxib is
0.8 ± 0.1. Interestingly, the experimental range of the slopes overlap, suggesting a possible
universal slope value, at least above Tg. Nevertheless, further substances should be studied
to be able to postulate a possible general model that could predict tc for a given τα. It is
also interesting to note that the dependence of tc on τα is sublinear.
If the temporal dependence of the crystallization were Avrami-like,52,53 then the normal-
ized static-permittivity difference would follow:54
ˆ(t) = 1− exp(−K(t− t0)n) (7)
where K is the temperature-dependent crystallization rate and n is the Avrami exponent,
which should be a constant that depends exclusively on the crystalline morphology and
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Figure 6: Plots of characteristic crystallization time (tc) versus average α relaxation time
above Tg in STP (circles), indomethacin (triangles) and celecoxib (squares). Values for
indomethacin and celecoxib were obtained from reference.31 Error bars are provided when n
= 3; otherwise, the crystallization time is the average of two determinations.
crystallization mechanism.55 Fig. 7(a) displays the Avrami plot at all studied temperatures.
The normalized static-permittivity difference ˆ is shown as a function of the time elapsed
from the crystallization onset (t− to) for each crystallization temperature. The inset shows
the Arrhenius plot of the onset time, to. If the Avrami law were obeyed, each isothermal curve
should look like a straight line, with constant slope equal to n. However, this is clearly not
the case in Fig. 7(a). To better visualize this fact, in Fig. 7(b) we have plotted the value of
the effective (time-dependent) Avrami exponent for the temperature at which crystallization




As It is evident form Fig. 7(b) that the Avrami exponent is far from constant. In order
to unambiguously state that the Avrami’s law is not followed by this compound the errors
affecting the data have been calculated using a block average technique. As it can be seen
in Fig. 7 the variation of the curve is greater than the calculated errors, supporting again
that Avrami’s law is not followed. The inset in the same figure shows a curve obtained
15
by the subtraction of a linear curve to the experimental one in order to investigate if the
exponent is constant or not in the most straightforward way. Again, the points seem not to
follow an Avrami law, taking into account the obtained errors. Finally we have investigated
if a different choice of to could be possibly causing the variations on the Avrami exponent.
However to is only affecting an horizontal and vertical displacement of the curve of Fig. 7(b)
and, thus, it cannot cause a deviation from linearity in Fig. 7(b). At higher isothermal
crystallization temperature, the effective Avrami coefficient is observed to vary between 1
and 2 (not shown). A value in this range would suggest a one-dimensional crystallization of
STP into needle-like crystallites,56 which is however not observed (see below). It is worth
pointing out that similar departures from the Avrami law have been observed also in other
compounds.57
To understand the reason underlying the failure of the Avrami law we performed diffrac-
tion experiments and observations of the crystallization process with an optical microscope.
One possible cause of failure of the Avrami law, could be the existence of different polymorphs
of STP, leading to the formation of crystallites with distinct structures and morphology, for
example, as it happens for many pharmaceutical compounds.58–63 This possibility is dis-
carded by our X-ray diffraction measurements. Fig. 8 shows the diffractograms obtained at
(300 ± 1) K on the as-stored crystalline material, at (273 ± 1) K right after quenching from
liquid state and at (300 ± 1) K after reheating.
It can be observed that the initial and recrystallized material display the same struc-
ture, and that the supercooled sample is indeed of glassy nature, as evidenced by the broad
amorphous background. Within this broad feature, some crystalline Bragg reflections can be
observed at 2θ = 6, 15.6, 15.9, 18.8 and 19.1. These correspond to the presence of a fraction
of crystalline material. This behavior coincides with that observed by optical microscopy
on molten drops at ambient temperature: while some drops recrystallized within approxi-
mately 10 minutes, some others remained liquid for much longer times. Fig. 9 shows of the
crystallization of pure STP as observed with an optical microscope.
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Figure 7: (a) Avrami plot of the normalized static-permittivity difference ˆ as a function of
the time elapsed from the crystallization onset (t− to), for all five isothermal crystallization
temperatures studied. Inset: Arrhenius plot of the onset time to. (b) Effective Avrami
exponent (Eq. (8)), as a function of the time elapsed from the crystallization onset, for
the measuring temperature of 273.0 K. Inset: Curve obtained by the subtraction of a linear
curve to the experimental one.
17
Figure 8: X-ray diffraction pattern of the as received STP powder at 300 K (blue), super-
cooled liquid at 273 K (green) and recrystallized sample at 300 K (red). Inset: Zoom-in of
the data at low scattering angles.
Figure 9: Crystallization of STP observed through an optical microscope with back-light
illumination.
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In the first photograph two regions can be clearly distinguished: a circular drop on the
bottom and a bigger liquid domain on top, whose boundary is signaled by a white line. The
dark region on the top right corner is the part of STP that is already crystalline. As time
advances the growth of the crystal is observed. It can be noted in the first three photographs
that the process is not unidirectional but rather results in a fractal 3D-morphology. Moreover,
no other nucleation site appears in the liquid portion, apart from the first crystal. In other
words, it is hard for STP crystals to nucleate, so that recrystallization generally proceeds
from a single point (seed) towards the rest of the available liquid in all possible directions.
This is evident also in the center and lower panels of Fig. 9, where a circular drop of liquid
STP is visible. Such drop only starts to crystallize when crystallization of the larger liquid
domain is complete. In picture D the growing crystal reaches the boundary with the single
drop breaking its surface. As soon as the liquid of the second drop comes in contact with
the crystal, it produces a burst of further crystal growth. In E the remaining part of the
smaller drop is half crystallized and at F the process is complete. Black regions indicate
higher crystalline structures, which are out of focus with respect to the height of the original
liquid. It can be then affirmed that the crystalline phase grows as a function of the shape
and size of the domains of the supercooled liquid, and that nucleation is the limiting step for
crystallization. This, together with the fractal-like crystal growth, helps rationalizing why
the Avrami theory is not fully satisfied. The Avrami exponent can in fact change during
crystallization if the growth morphology changes.64
Conclusions
By studying Stiripentol (STP) in its supercooled liquid and glass state, three different relax-
ations were identified: the α relaxation peak, corresponding to the collective reorientation
of the STP molecules, a Johari Goldstein β relaxation that is the precursor of the α process
according to the Coupling model, and a γ relaxation which corresponds to an intramolecu-
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lar relaxation. The Tg of the material was determined both by dielectric spectroscopy and
calorimetry, obtaining Tg = 246.2± 0.5 K and Tg = 248± 1 K, respectively.
Isothermal crystallization of STP was studied at temperatures between 273.0 and 293.0 K. It
is found that the Avrami law is not obeyed. This happens because STP has difficulties when
nucleating, and possibly also because the crystalline phase grows in a fractal 3D morphology.
It appears that supercooled liquid STP requires in general relatively high temperatures to
produce a crystalline nucleus, from which crystal growth proceeds so fast, that no other
nucleation site is generated during crystallization of a given liquid domain. As observed by
means of X-ray diffraction, the initial solid and the recrystallized material display the same
structure, which indicates that no other polymorph of STP appears at ambient pressure.
A sublinear correlation is found between the characteristic crystal-growth time and the col-
lective relaxation dynamics. This correlation was observed also in other substances, and
suggests a general correlation at temperatures above Tg to predict a substance’s crystalliza-
tion time as a function of temperature. Further materials should be studied so as to test
this possibility.
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